Precision Medicine for Pulmonary Vascular Disease: The Future Is Now (2023 Grover Conference Series).

IF 2.2 4区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pulmonary Circulation Pub Date : 2025-01-02 eCollection Date: 2025-01-01 DOI:10.1002/pul2.70027

Lindsay M Forbes, Natalie Bauer, Aritra Bhadra, Harm J Bogaard, Gaurav Choudhary, Kara N Goss, Stefan Gräf, Gustavo A Heresi, Rachel K Hopper, Arun Jose, Yunhye Kim, Timothy Klouda, Tim Lahm, Allan Lawrie, Peter J Leary, Jane A Leopold, Suellen D Oliveira, Sasha Z Prisco, Ruslan Rafikov, Christopher J Rhodes, Duncan J Stewart, Rebecca R Vanderpool, Ke Yuan, Alexsandra Zimmer, Anna R Hemnes, Vinicio A de Jesus Perez, Martin R Wilkins

{"title":"Precision Medicine for Pulmonary Vascular Disease: The Future Is Now (2023 Grover Conference Series).","authors":"Lindsay M Forbes, Natalie Bauer, Aritra Bhadra, Harm J Bogaard, Gaurav Choudhary, Kara N Goss, Stefan Gräf, Gustavo A Heresi, Rachel K Hopper, Arun Jose, Yunhye Kim, Timothy Klouda, Tim Lahm, Allan Lawrie, Peter J Leary, Jane A Leopold, Suellen D Oliveira, Sasha Z Prisco, Ruslan Rafikov, Christopher J Rhodes, Duncan J Stewart, Rebecca R Vanderpool, Ke Yuan, Alexsandra Zimmer, Anna R Hemnes, Vinicio A de Jesus Perez, Martin R Wilkins","doi":"10.1002/pul2.70027","DOIUrl":null,"url":null,"abstract":"<p><p>Pulmonary vascular disease is not a single condition; rather it can accompany a variety of pathologies that impact the pulmonary vasculature. Applying precision medicine strategies to better phenotype, diagnose, monitor, and treat pulmonary vascular disease is increasingly possible with the growing accessibility of powerful clinical and research tools. Nevertheless, challenges exist in implementing these tools to optimal effect. The 2023 Grover Conference Series reviewed the research landscape to summarize the current state of the art and provide a better understanding of the application of precision medicine to managing pulmonary vascular disease. In particular, the following aspects were discussed: (1) Clinical phenotypes, (2) genetics, (3) epigenetics, (4) biomarker discovery, (5) application of precision biology to clinical trials, (6) the right ventricle (RV), and (7) integrating precision medicine to clinical care. The present review summarizes the content of these discussions and the prospects for the future.</p>","PeriodicalId":20927,"journal":{"name":"Pulmonary Circulation","volume":"15 1","pages":"e70027"},"PeriodicalIF":2.2000,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11693987/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pulmonary Circulation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/pul2.70027","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Pulmonary vascular disease is not a single condition; rather it can accompany a variety of pathologies that impact the pulmonary vasculature. Applying precision medicine strategies to better phenotype, diagnose, monitor, and treat pulmonary vascular disease is increasingly possible with the growing accessibility of powerful clinical and research tools. Nevertheless, challenges exist in implementing these tools to optimal effect. The 2023 Grover Conference Series reviewed the research landscape to summarize the current state of the art and provide a better understanding of the application of precision medicine to managing pulmonary vascular disease. In particular, the following aspects were discussed: (1) Clinical phenotypes, (2) genetics, (3) epigenetics, (4) biomarker discovery, (5) application of precision biology to clinical trials, (6) the right ventricle (RV), and (7) integrating precision medicine to clinical care. The present review summarizes the content of these discussions and the prospects for the future.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

肺血管疾病的精准医学：未来就是现在（2023 Grover会议系列）。

肺血管疾病不是一种单一的疾病；相反，它可以伴随各种影响肺血管系统的病理。随着强大的临床和研究工具的日益普及，应用精准医学策略来更好地表型、诊断、监测和治疗肺血管疾病越来越有可能。然而，在实现这些工具的最佳效果方面存在挑战。2023 Grover系列会议回顾了研究前景，总结了当前的艺术状态，并提供了更好的理解精准医学在肺血管疾病管理中的应用。重点讨论了以下几个方面：(1)临床表型，(2)遗传学，(3)表观遗传学，(4)生物标志物发现，(5)精准生物学在临床试验中的应用，(6)右心室（RV），(7)精准医学与临床护理的结合。本综述总结了这些讨论的内容和对未来的展望。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Pulmonary Circulation Medicine-Pulmonary and Respiratory Medicine

CiteScore

4.20

自引率

11.50%

发文量

153

审稿时长

15 weeks

期刊介绍： Pulmonary Circulation''s main goal is to encourage basic, translational, and clinical research by investigators, physician-scientists, and clinicans, in the hope of increasing survival rates for pulmonary hypertension and other pulmonary vascular diseases worldwide, and developing new therapeutic approaches for the diseases. Freely available online, Pulmonary Circulation allows diverse knowledge of research, techniques, and case studies to reach a wide readership of specialists in order to improve patient care and treatment outcomes.